OBJECTIVES: According to World Health Organisation, type-2 diabetes has recently escalated in all age groups and is now being identified in younger and younger age groups, including adolescents and children, especially in high-risk population. This underscores the need for mass awareness and screening programmes to detect diabetes at an early stage and early age cost effectively. For this purpose we have planned to use a simplified Indian Diabetes Risk Score [IDRS] for prediction of diabetes in young adolescents of Bharati Vidyapeeth Deemed University Medical College. METHODS: A total of 261 students of said Medical College will be screened using IDRS which includes age, family history of diabetes, exercise status and Waist circumference. After scoring them they will be categorised into mild, moderate and high risk group. In students who are having score more than 50, Random Capillary Blood Glucose (RCBG) were assessed with the help of glucometer. RESULTS: We have assessed 261 students till now. It was observed that 5% ,55% & 38% students in high, Moderate & Low risk group respectively for developing type 2 D.M. Mean abdominal obesity in high risk students was 101.95± 5.76 as compared to 79.17 ± 11.08 in moderate and low risk students(p<0.0001). Family history of diabetes in either or both parents was present in 25% students. 63% students were having sedentary lifestyle. Mean RCBG in students having score more than 50 was 97.33 ±9.68 mg/dl. Also, 3 students were having RCBG >103mg/dl. CONCLUSIONS: This underscores the need for further investigations. IDRS is the simplest way to screen large population. To prevent and to postpone the risk of type 2 diabetes mellitus, health education programme, exercise and diet planning can be recommended for these students.Thus this mayprove as a cost effective solution of detection of risk of type-2 diabetes mellitus. 
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COST-EFFECTIVENESS ANALYSIS OF USING HYPOGLYCEMIC AGENTS (LINAGLIPTIN, SAXAGLIPTIN, SITAGLIPTIN, VILDAGLIPTIN, GLIMEPIRIDE AND GLIBENCLAMIDE) WITH METFORMIN IN DIABETES IN COLOMBIA
OBJECTIVES:
To Analyze the cost-effectiveness of using oral hypoglycemic agents (linagliptin, saxagliptin, sitagliptin, vildagliptin, glimepiride and glibenclamide) each associated with metformin, to control type-2 diabetes mellitus in patients with inadequate glycemic control, from a third-party's payer perspective. METHODS: A Monte Carlo-type Markov model was used to simulate disease natural history. The outcomes of interest were fatal infarct, acute myocardial infarction, stroke, nephropathy, moderate or severe hypoglycemia and changing of treatment, expressed in years of life (LY). Drug costs were taken from market average at prices for 2012 expressed in Colombian pesos. Direct medical costs were taken from insurers and individual health benefit records (SISMED). A discount rate of 5% was applied both to cost and outcomes. RESULTS: As a main outcome the measures of life years (LY) are nearly similar for each combined treatment. However linagliptin is barely a most effective treatment with 13.71 life years discounted, followed by sitagliptin and vildagliptin with 13.70 and 13.60 life years discounted respectively. Similarly, linagliptin is the least expensive (COP$69,396,763 discounted annually) while saxagliptin and vildagliptin have a cost of COP$71,941,693 and COP$71,713,900 discounted, respectively. It was found that linagliptin, vildagliptin and sitagliptin are nearly similar with respect to life years (LY) and each one is placed below the efficient frontier. Among the oral hypoglycemic agents analyzed, only three (linagliptin, vildagliptin and sitagliptin) are cost-effectives, being linagliptin the most. Glibenclamide is the only technology included in the Colombian healthcare benefits plan and is the least effective and the most expensive one. CONCLUSIONS: Linagliptin, sitagliptin and vildagliptin each one added to metformin is nearly similar with respect to life years (LY) and to cost-effectives. Linagliptin appears to be an advisable option due to its lower cost and its fewer macro and micro vascular events, for diabetic patients with inadequate glycemic control in Colombia. 
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COST-EFFECTIVENESS OF THERAPY CONVERSION FROM HUMAN SOLUBLE INSULIN TO INSULIN ASPART IN PATIENTS WITH TYPE-2 DIABETES IN A CHINESE SETTING
OBJECTIVES:
To evaluate the long-term cost-effectiveness of switching from human soluble insulin (HI) to insulin aspart (IAsp) in patients with type 2 diabetes mellitus (T2DM) in a Chinese setting. METHODS: A published and validated computer simulation model of diabetes (CORE Diabetes Model) was used to project long-term (30 years) life expectancy, quality-adjusted life years (QALY) and direct medical costs. Baseline cohort characteristics and treatment effects were based on Asian subgroup (n=154, including patients from China, Bangladesh, India, Pakistan, Indonesia, South Korea, Malaysia, Philippines, Singapore and Taiwan) in A1chieve study which is a prospective, multi-center, open-label, non-interventional, 24-week observational study. Treatment costs were derived from drug retail prices in Chinese market. The diabetes management and complication costs were obtained from Chinese published data. Projections were made from a societal perspective and an annual discounting rate of 3% was used for both costs and health outcomes simulation. One-way sensitivity analysis was performed. RESULTS: Therapy conversion to IAsp would result in increased life expectancy by 0.81 years per patient (13.93 vs. 13.12) and QALY by 1.44 QALYs per patient (9.87 vs. 8.43), due to reduced incidences of diabetes-related complications. Treatment and management costs of diabetes were increased by CNY (Chinese Yuan) 11,690 (48,850 vs. 37,160) and 1,982 (39,924 vs. 37,942) respectively. However, the costs of complications, including cerebrovascular disease, renal complications, ulcer/amputation/ neuropathy, eye complications, and hypoglycemia events, were reduced by CNY 199, 028 (102, 590 vs. 301, 618) , resulting in total direct medical cost saving of CNY 185,357. Sensitivity analyses demonstrated robustness of the results. CONCLUSIONS: Switching from HI to IAsp in T2DM patients in China was associated with not only improvement of life expectancy and QALYs, but also significant reduction in total direct medical costs. Therapy conversion to IAsp from HI is a cost-saving treatment strategy for T2DM patients in a Chinese setting. 
PDB46 SHORT AND LONG-TERM COST-EFFECTIVENESS OF STARTING INSULIN DETEMIR IN INSULIN-NAÏVE PEOPLE WITH TYPE-2 DIABETES
PDB47 SHORT AND LONG-TERM COST-EFFECTIVENESS OF SWITCHING THERAPY FROM BIPHASIC HUMAN INSULIN 30 TO BIPHASIC INSULIN ASPART 30 IN PEOPLE WITH TYPE-2 DIABETES
OBJECTIVES:
To assess the cost-effectiveness (CE) of switching from biphasic human insulin 30 (BHI 30) ± oral glucose-lowering drugs (OADs) to biphasic insulin aspart 30 (BIAsp 30) ± OADs in people with type 2 diabetes (T2D) in countries in different economic circumstances based on observational data gathered in routine clinical practice. METHODS: The A1chieve ® study assessed safety and outcomes over 24 weeks in 66,726 people with T2D starting insulin analog therapy. The CE analyses included people switching to BIAsp 30 in Saudi Arabia (n=401), India (n=866) and Indonesia and Malaysia based on people in 4 ASEAN countries (n=175). Data were collected on clinical effectiveness, adverse events, and outcomes using the EQ-5D questionnaire. CE analyses used the IMS CORE diabetes model with 1 and 30 year time horizons, with country-specific costs for complications and therapies and background mortality rates. Incremental cost-effectiveness ratios (ICERs) are expressed as cost/QALY in local currencies, USD and in fractions of local GDP per capita based on switching from BHI 30 to BIAsp 30. CE was pre-defined as <3*GDP. RESULTS: One-year ICERs were: Saudi Arabia (SAR 12,913; USD 3,443; GDP 0.17), India (INR 36,001; USD 649; GDP 0.44), Indonesia (IDR 120, 507, 714; USD 12, 520; GDP 2.92), Malaysia (MYR 40, 321; USD 13, 180 ; GDP 3.08). 30-year ICERs were: Saudi Arabia (SAR 837; USD 223; 0.03 GDP), India (INR 21,696; USD 391, GDP 0.26), Indonesia (IDR 51, 416, 633; USD 5, 342; GDP 1.25), Malaysia (MYR 19, 967; USD 5, 342; GDP 1.25) . Sensitivity analyses on the 30 year time horizon showed the findings to be robust. CONCLUSIONS: Switching from BHI 30±OADs to BIAsp 30±OADs in T2D as performed in the A1chieve ® study was found to be cost-effective across all country settings at 1 and 30 year time horizons. The Malaysian analyses showed borderline cost-effectiveness using 1 year time horizon but cost-effectiveness assuming 30 year time horizon.
PDB48 SHORT AND LONG-TERM COST-EFFECTIVENESS OF SWITCHING THERAPY FROM INSULIN GLARGINE TO BIPHASIC INSULIN ASPART 30 IN PEOPLE WITH TYPE-2 DIABETES IN SAUDI ARABIA AND INDIA
Home PD 1 , Soewondo P 2 , Shafie AA 3 , AlRaddady K 4 , Baadbad R 5 , Hammerby E 6 , Nikolajsen A 6 , Andersen MFB 7 , Henriksen O 7 1 University of Newcastle upon Tyne, Newcastle upon Tyne, UK, 2 University of Indonesia, Jakarta, Indonesia, 3 Universiti Sains Malaysia, Penang, Malaysia, 4 King Saud Medical City, Riyadh, Saudi Arabia, 5 Pharmacoeconomics Center of KSMC, Riyadh, Saudi Arabia, 6 Novo Nordisk A/S, Søborg, Denmark, 7 Last Mile P/S, Copenhagen K, Denmark OBJECTIVES: To assess the cost-effectiveness (CE) of switching therapy from insulin glargine (IGlar) ± oral glucose-lowering drugs (OADs) to biphasic insulin aspart 30 (BIAsp 30) ± OADs in people with type 2 diabetes (T2D) in Saudi Arabia and India based on observational data gathered in routine clinical practice. METHODS: The A1chieve ® study assessed safety and outcomes over 24 weeks in 66,726 people with T2D starting insulin analog therapy. Most participants (96%) stated better glycemic control as reason to switch therapy, 31% also stated problems with hypoglycemia as reason of switch. The CE analyses included people switching to BIAsp 30 in Saudi Arabia based on people in 7 Gulf countries (n=103) and in India (n=191). Data were collected on clinical effectiveness, adverse events, and patient reported outcomes using the EQ-5D questionnaire. CE analyses used the IMS CORE diabetes model with 1 and 30-year time horizons, with country-specific costs for complications and therapies and country-specific background mortality rates. Incremental cost-effectiveness ratios (ICERs) are expressed as cost/QALY in local currencies, USD and in fractions of local GDP per capita based on switching from IGlar to BIAsp 30. CE was pre-defined as <3*GDP. RESULTS: For both a 1 and 30 year time horizons the switch was found to be less costly and have better outcomes. 1-year ICERs were: Saudi Arabia (SAR -8,958; USD -2,388; GDP -0.12) and India 194; 086; . 30-year ICERs were: Saudi Arabia 242; 798; and India (INR -55,914; USD -1,008; GDP -0.68). Sensitivity analyses on the 30 year time horizon showed the findings to be robust. CONCLUSIONS: Switching therapy from IGlar to BIAsp 30 in T2D as performed in the A1chieve ® study was found to be dominant across both country settings based on a 1 and 30 year time horizon.
PDB49 SHORT AND LONG-TERM COST-EFFECTIVENESS OF STARTING BIPHASIC INSULIN ASPART 30 IN INSULIN-NAÏVE PEOPLE WITH TYPE-2 DIABETES
Home PD 1 , Soewondo P 2 , Hussein Z 3 , Shafie AA 4 , AlRaddady K 5 , Baadbad R 6 , Hammerby E 7 , Nikolajsen A 7 , Andersen MFB 8 , Henriksen O 8 1 University of Newcastle upon Tyne, Newcastle upon Tyne, UK, 2 University of Indonesia, Jakarta, Indonesia, 3 Hospital Putrajaya, Putrajaya, Malaysia, 4 Universiti Sains Malaysia, Penang, Malaysia, 5 King Saud Medical City, Riyadh, Saudi Arabia, 6 Pharmacoeconomics Center of KSMC, Riyadh, Saudi Arabia, 7 Novo Nordisk A/S, Søborg, Denmark, 8 Last Mile P/S, Copenhagen K, Denmark OBJECTIVES: To assess the cost-effectiveness (CE) of starting biphasic insulin aspart 30 (BIAsp 30) therapy ± oral glucose-lowering drugs (OADs) in people with type 2 diabetes (T2D) in countries in different economic circumstances based on observational data gathered in routine clinical practice. METHODS: The A1chieve ® study assessed safety and outcomes over 24 weeks in 66,726 people with T2D starting insulin analog therapy. The CE analyses included people starting BIAsp 30 in Saudi Arabia (n=901), India (n=7,546), Indonesia (n=153), in Malaysia based on people in 4 ASEAN countries (n=430) and in Algeria based on people in 3 countries in North-West Africa (n=279). Data were collected on clinical effectiveness, adverse events, and patient reported outcomes using the EQ-5D questionnaire. CE analyses used the IMS CORE diabetes model with 1 and 30 year time horizons, with country-specific costs for complications and therapies and background mortality rates. Incremental cost-effectiveness ratios (ICER) are expressed as cost/QALY in local currencies, USD and in fractions of local GDP per capita based on starting BIAsp 30. CE was pre-defined as <3*GDP. RESULTS: 1-year ICERs were: Saudi Arabia (SAR 10,741; USD 2,864; GDP 0.14), India (INR 35,182; USD 635; GDP 0.43), Indonesia (IDR 40, 487, 477; USD 4, 207 ; GDP 1.2), Malaysia (MYR 13,061; USD 4,270; GDP 1.00), Algeria (DZD 246,422; USD 3,095, GDP 0.73). 30-year ICERs were: Saudi Arabia (SAR -3,004; USD -801; GDP -0.04), India (INR 20,516; USD 370; GDP 0.25), Indonesia (IDR 15,710,332; USD 1,632; GDP 0.47), Malaysia (MYR 8,038; USD 2,627; GDP 0.61), Algeria (DZD 155,659; USD 1,955; GDP 0.46). Sensitivity analyses on the 30 year time horizon showed the findings to be robust. CONCLUSIONS: Starting BIAsp 30 in T2D as performed in the A1chieve ® study was found to be cost-effective across all country settings based on a 1 and 30 year time horizon. 
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COST-EFFECTIVENESS OF SWITCHING TO INSULIN ASPART FROM HUMAN SOLUBLE INSULIN IN CHINESE PATIENTS WITH TYPE-2 DIABETES ON A BASAL-BOLUS REGIMEN
OBJECTIVES:
To evaluate long-term health economic outcomes of switching from human soluble insulin (HI) to insulin aspart (IAsp) on a basal-bolus regimen in type 2 diabetes mellitus (T2DM) patients in a Chinese setting. METHODS: The previously published and validated IMS Core Diabetes Model was used to project long-term life expectancy, quality-adjusted life years (QALY) and total direct medical costs. Baseline patient characteristics and treatment effects were based on Asian subgroup (n=185, countries including China, Bangladesh, India, Pakistan, Indonesia, South Korea, Malaysia, Philippines, Singapore and Taiwan) in A1chieve study which is a prospective, multi-centre, open-label, non-
